Pyc Therapeutics Ltd has released a press release.
Commencement of First Clinical Study in RP11
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Second Drug Program Progressing to Human Trials
- FDA Clears PYC to Commence First Human Trials in RP11
- VP-001 IND Lodgement
- Successful Toxicology Studies Pave Way for Human Trials
- Central Nervous System Drug Program Added to PYC Pipeline
Later from PYC Therapeutics
- Successful Completion of $30m Placement
- Placement Supporting Document
- First patient dosed in eye disease clinical trial
- Successful Toxicology Results Pave Way for Phase 2 Trial
- PYC Receives FDA Fast Track Designation
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics